Jason Assad

Jason Assad has a diverse work experience spanning multiple industries. Jason began their career in 2018 as the Head of Corporate Communications at Amergent Hospitality Group, Inc. In 2020, they joined 180 Life Sciences Corp. as the Director of Corporate Communications, where they focused on developing drugs for inflammatory diseases. The following year, Jason joined Hoth Therapeutics, Inc. as the Head of Investor Relations, working on early-stage pharmaceutical research and development. In 2021, they took on the role of Investor Relations at Processa Pharmaceuticals, a company focused on improving the survival and quality of life for patients with unmet medical needs. Later in the year, Jason became the Director of Corporate Communications at Unrivaled Brands, a multi-state vertically integrated company in the cannabis sector. Moving into 2022, they served as the Communications Strategist at Gain Therapeutics, a biotechnology company specializing in allosteric small molecule therapies. Jason then took on the role of Head of Corporate Communications at Crown Electrokinetics. Currently, Jason is the Communications Strategist at Coya Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary treatments for systemic inflammation and neuroinflammation. In 2023, they will also serve as the Head of Corporate Communications at TeraWulf. Throughout their career, Jason has gained expertise in corporate communications, investor relations, and strategic advisory services.

Jason Assad attended The University of Georgia from 1989 to 1993, where they earned their Bachelor's Degree in Public Relations.